Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 40 (Nov 24, 2019)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously be suspended for an indefinite period on May 15, 2019. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) and (6) of the Health Professions Act.


May 15, 2019
(November 24, 2019 - Registration reinstated)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 15, 2019. The Agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacy Technician Registrant 3 (Nov 22, 2019)

The Inquiry Committee has reinstated the pharmacy technician registrant’s registration which had previously been suspended for an indefinite period on September 1, 2018. Pursuant to section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacy technician registrant whereby the pharmacy technician registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all recommendations and treatments prescribed or directed by the registrant’s physicians;
     
  2. To comply with every term of a routine medical monitoring program for a minimum of 36 consecutive months;
     
  3. To be restricted from handling, dispensing and packaging narcotics, controlled substances and sedatives, but not to be restricted from to be working in the same area and/or room where medications are stored, supplied and dispensed by other employees; 
     
  4. To be restricted from disposing or dealing with wastage or breakage of or otherwise handle any narcotics, controlled substances and sedatives;
     
  5. To be permanently restricted to working daytime hours with the latest time being 11:00pm on certain days;
     
  6. To ensure all managers and employers, with whom the registrant gains employment, are aware of the registrant’s limits and conditions on the registrant’s registration pursuant to the Agreement;
     
  7. To inform the College of the registrant’s place of employment as a pharmacy technician and report any changes to the location or management within 48 hours of such change; and
     
  8. To comply with the physician’s recommended schedule for a gradual return to work. 

September 1, 2018
(November 22, 2019 - Registration Reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacy technician registrant to suspend her registration as a pharmacy technician for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The registered pharmacy technician registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 14 (Oct 18, 2019)

Pharmacist registrant 14 has satisfied the terms of an Agreement reached with the Inquiry Committee on January 23, 2013. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed by the Inquiry Committee. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act


January 23, 2013
(October 18, 2019 – Limits and conditions removed) 

The Inquiry Committee has reinstated pharmacist registrant’s registration which was previously suspended for an indefinite period of time on December 10, 2012. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with pharmacist registrant to reinstate his registration to Full Pharmacist subject to certain limits and conditions, effective January 23, 2013. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


December 24, 2012
(January 23, 2013 – Registration reinstated) 

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further disposition by the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 37 (Oct 15, 2019)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on June 25, 2018. Pursuant to section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will adhere to routine medical monitoring program with the institution currently involved in the Registrant’s case and remain on the program for two years;

  2. In the event of any interruption to the agreed monitoring schedule set out by the medical monitoring program, the Registrant will advise the College of the interruption as soon as possible and provide an explanation for the interruption; and

  3. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in the Registrant’s care.  

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purpose of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


June 25, 2018
(October 15, 2019 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with pharmacist registrant to suspend registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 31 (Jul 19, 2019)

Pharmacist registrant 31 has satisfied the terms of an Agreement reached with the Inquiry Committee on August 22, 2017. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


August 22, 2017
(July 19, 2019 - Limits and conditions removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on March 20, 2017. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will adhere to routine medical monitoring program with the institution currently involved in the Registrant’s case and remain on the monitoring program for three years;

  2. The Registrant will not work alone in a pharmacy, and will, at all times, have another pharmacist or pharmacy technician/assistant/staff on site at all times;

  3. The Registrant will not have any access whatsoever, on or off-duty, to the narcotic safe in any pharmacy;

  4. The Registrant will not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  5. The Registrant will not dispense own medications;

  6. The Registrant shall disclose to the pharmacy manager/or employer the limits and conditions on the Registrant’s license pursuant to the agreement prior to the commencement of new employment at any pharmacy;

  7. The Registrant will ensure that the pharmacy manager and/or employer with whom the Registrant secures employment submits a written statement to the College declaring their awareness of the Registrant’s medical condition and the agreement;

  8. The Registrant will notify the College, in writing or via e-mail, of places of employment as a pharmacist and report any changes to the location of employment within 48 hours of such change. A reportable change to the Registrant’s place of employment contemplates both commencement and termination of employment;

  9. The Registrant will be restricted from acting in the following roles in the Registrant’s practice:

    • Be a manager of a pharmacy;
    • Be a director of a corporation that owns a pharmacy; and
    • Act as a preceptor.

     

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


March 20, 2017
(AugUst 22, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement by consent with the pharmacist registrant to voluntarily suspend registration as a pharmacist effective March 20, 2017. The agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Pharmacist Registrant 41 (Jul 3, 2019)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective July 3, 2019. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Tejani, Diamondali Alladin (Jun 20, 2019)
(March 15, 2020 - REGISTRATION REINSTATED)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Diamondali Alladin Tejani (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183.

  2. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  3. Effective date: June 20, 2019

  4. Name of registrant: Diamondali Alladin Tejani

  5. Location of Practice: Vancouver, BC

  6. Admissions and Acknowledgements:

    Between July 8, 2016 and November 25, 2016, while he was owner, manager and pharmacist, several pharmacy practice deficiencies were identified. The Registrant has admitted and/or acknowledged the following:

    1. Pharmacy staff provided cash incentives in exchange for daily dispense prescriptions;

    2. He knew or should have known that a pharmacist/patient consultation was required for new and refill daily dispense prescriptions;
       
    3. On several occasions, pharmacy staff entered and did not reverse daily dispense prescriptions on PharmaNet when the patient did not attend the pharmacy;

    4. Pharmacy staff dispensed several prescriptions contrary to the prescriber’s instructions (by providing missed doses for a prescription that was required to be daily dispensed); and
       
    5. Pharmacy staff dispensed several prescriptions without prescription labels.

  7. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee of CPBC, wherein the Registrant consented to the following terms (in part):

    1. To suspend his registration as a pharmacist for 180 consecutive days commencing September 18, 2019 to March 15, 2020.

    2. To not be a pharmacy manager, director, owner (direct or indirect), shareholder in a corporation that owns a pharmacy and preceptor for a period of two years from the date that his suspension ends (March 16, 2020 to March 15, 2022);
       
    3. At his own costs, to complete and pass an ethics course for healthcare professionals; and

    4. To pay a $15,000.00 fine.
       
  8. Rationale:

    The Inquiry Committee determined that the totality of the Registrant’s past and present conduct raised serious concerns about his ethical and professional standards in the course of his practice at the pharmacy as a pharmacist, pharmacy manager and owner. The Inquiry Committee determined that his poor standard of practice warranted limits and conditions imposed on his licence, in addition to a fine and a requirement to take an ethics course in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. 

Ladha, Azizabegum (Jun 7, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“the College”) conducted an investigation into the practice of Azizabegum Ladha (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: June 7, 2019

  3. Name of registrant: Azizabegum Ladha 

  4. Location of Practice: Surrey, BC

  5. Admissions and Acknowledgements:

    Between January 2016 and July 2016, the Registrant worked at two different pharmacies, one of which she was the pharmacy manager. During this time, the following pharmacy practice issues and contraventions of legislation occurred, of which she had direct involvement:

    1. She did not provide adequate pharmacist/patient consultations for refill medications;

    2. She dispensed Schedule I medication in a manner that was not authorized in the prescriptions;

    3. She processed inaccurate and non-current transactions on PharmaNet;

    4. She did not review PharmaNet prior to dispensing prescriptions; and

    5. She did not take reasonable steps to confirm the identity of a patient before dispensing medication for this patient.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. To suspend her registration as a pharmacist for a total of 30 consecutive days;

    2. To not be a pharmacy manager and preceptor for a period of 18 months from the date that her suspension ends;
       
    3. To pay a fine in the amount of $5,000.00; and

    4. To successfully complete and pass the “BC Pharmacy Manager Training Program” offered by the British Columbia Pharmacy Association.

  7. Rationale:

    The Inquiry Committee was concerned that the Registrant had previously consented to undertakings and a reprimand related to her pharmacy practice, from which she should have remediated. However, in this current matter she contravened practice standards which could have endangered patient health. The Inquiry Committee therefore considered the totality of the Registrant’s conduct to be serious, and that she required further remediation and deterrence in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.

Tam, Sing Man (May 27, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of Sing Man Tam (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: May 27, 2019

  3. Name of registrant: Sing Man Tam​

  4. Admissions and Acknowledgements:

    On October 13, 2015, the College received correspondence from the BC Ministry of Health regarding potential pharmacy practice concerns at the Pharmacy, arising from a PharmaCare Audit of the Pharmacy that covered the time period between September 1, 2012 and August 31, 2014 (the “Audit Period”).  Further to the College’s investigation of those practice concerns, the Registrant acknowledged

    1. prescriptions were missing date or quantity to dispense,

    2. prescriptions were filled under the incorrect prescriber,
       
    3. a prescription was dispensed for the wrong dose,

    4. prescriptions were written by the prescriber as daily witness ingestion but were processed under the Drug Identification Number (“DIN”) for methadone given without direct interaction
       
    5. a prescription was written by the physician for daily witness ingestion but was processed under the DIN for delivery of methadone, without authorization,

    6. medication reviews were submitted to PharmaNet that did not have any supporting documentation,

    7. prescriptions for Hepatitis C medications were not submitted to PharmaNet on the day of claimed dispense,
       
    8. prescriptions were written by the physician as daily dispense, but were filled and submitted to PharmaNet as a 7 days’ supply, with no documentation of a prescriber’s authorization to do so,

    9. a prescription was filled as a verbal authorization with incomplete documentation,

    10. a methadone prescription was billed on a day marked as “missed” on the ingestion logs,

    11. a prescription adaptation was conducted without adequate documentation,

    12. a methadone prescription did not have a part fill accountability log, and

    13. a methadone prescription was provided as delivery without prescriber authorization.

  5. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. having a Letter of Reprimand placed permanently on his registration record;

    2. payment of a fine in the amount of $10,000;
       
    3. an undertaking to:

      1. not repeat the conduct to which this matter relates,
         
      2. thoroughly review and read legislation, standards and policies relevant to the conduct to which this matter relates, and thereafter submit a Declaration of Understanding regarding the legislation, standards and policies reviewed and read,
         
      3. complete the BC Pharmacy Manager Training Course as well as coursework relating to opioid agonist therapy,
         
      4. successfully complete the College’s Jurisprudence Exam,
         
      5. at all times prior to completing the BC Pharmacy Manager Training Course and successfully completing the College’s Jurisprudence Exam only provide the services of a pharmacist when a least one other full pharmacist registrant is present with him in the pharmacy, and
         
      6. at all times after delivering the Declaration of Understanding, completing the BC Pharmacy Manager Training Course and coursework relating to methadone maintenance treatment, and successfully completing the College’s Jurisprudence Exam, be knowledgeable of and abide by all legislation and policy governing the practice of pharmacy.

       

  6. Rationale:

    The Inquiry Committee considered that in this case, the cumulative weight of the practice deficiencies demonstrated inadequate diligence and oversight in the Registrant’s practice, noting that many of the substantiated practice deficiencies were substantive, and not simply administrative. Accurate record keeping and documentation are fundamental to providing safe pharmaceutical care. Therefore, the Committee considered the Registrant’s conduct to be serious, and that the Registrant required both remediation and deterrence in order to come into compliance. The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.

Damji, Salma Sadrudin (May 15, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacist of British Columbia (the “College”) conducted an investigation into the practice of Salma Sadrudin Damji (the “Registrant”), pursuant to section 33(4) of the Health Professions Act (“HPA”), R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: May 23, 2019

  3. Name of registrant: Salma Sadrudin Damji

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    Between January 2013 and January 2018, using a prescription pad from a medical clinic, the Registrant falsified prescriptions using three patient names and two physician names. The falsified prescriptions resulted in over sixty-two transactions processed on PharmaNet. The medications for these transactions were all Schedule I drugs, which required authorized prescriptions.

    The Registrant used the names and forged the signatures of two physicians as prescribers on these falsified prescriptions, all without the knowledge, consent or authorization of these physicians. The Registrant inappropriately used personal health information and created inaccurate PharmaNet records for the involved patients. By doing so, the Registrant placed the three patients whose name she used at risk of harm, in case their PharmaNet records ever needed to be accessed for legitimate reasons.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that include (but not limited to) the following:

    1. To suspend her registration as a pharmacist for a total of 90 days;

    2. To not be pharmacy manager, director, and/or owner of a pharmacy, shareholder in a corporation that owns a pharmacy, and a preceptor for pharmacy students for a period of three years;
       
    3. To write apology letters to persons affected by her conduct;

    4. To complete and successfully pass an ethics course for healthcare professionals; and

    5. To pay a fine of $1,000.

  7. Rationale:

    The Inquiry Committee considered that in this case, in addition to the serious misconduct, the Registrant placed herself and others at significant risk of harm, inappropriately used personal information, and created inaccurate PharmaNet records. Her actions were a serious contravention of standards in the Code of Ethics, and compromised the public’s trust in the pharmacy profession as a whole.

    The Inquiry Committee therefore determined that the Registrant required serious remediation and deterrence regarding her conduct. After also considering significant mitigating factors, the Inquiry Committee considered the terms of the Consent Agreement appropriate to protect the public, as well as send a clear message of deterrence to the profession.

Pages